Search results for "out"

showing 10 items of 13935 documents

Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

2020

Objectives: Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Methods: Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. Results: The median follow-up was 84.8 months. Radiation dose did not differ significantly as a function of sex, type of SP (solitary bone plasmacytoma or as extramedullary plasmacyt…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologySolitary plasmacytomaBone NeoplasmsMultiple myeloma; Plasma cell neoplasms; Radical radiotherapy; Solitary plasmacytomaEffective dose (radiation)law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologyRadical radiotherapyTumor sizebusiness.industryGeneral MedicinePlasma cell neoplasmMiddle Agedmedicine.diseasePrognosisSurvival AnalysisRadiation therapyPlasma cell neoplasm030104 developmental biologyTreatment OutcomeOncologyItaly030220 oncology & carcinogenesisDisease ProgressionFemalePlasma cell neoplasmsNeoplasm Recurrence LocalbusinessMultiple MyelomaSolitary plasmacytomaFollow-Up StudiesPlasmacytomaJournal of cancer research and clinical oncology
researchProduct

Effect of laser treatment on postural control parameters in patients with chronic nonspecific low back pain: a randomized placebo-controlled trial

2019

The management of nonspecific lumbar pain (NSLP) using laser irradiation remains controversial. A systematic review of recently published studies indicates that the effects of laser therapy are commonly assessed using only imperfect methods in terms of measurement error. The main objective of this study was to assess static postural stability using an objective tool in patients with chronic NSLP after laser irradiation at different doses and wavelengths. In total, 68 patients were included in the laser sessions and were randomly assigned into four groups: high-intensity laser therapy at 1064 nm and 60 J/cm2 for 10 min (HILT), sham (HILT placebo), low-level laser therapy at 785 nm and 8 J/cm…

0301 basic medicineAdultMaleMedicine (General)QH301-705.5PhysiologyImmunologyBiophysicsPlacebo-controlled studyOcean EngineeringPlaceboBiochemistrylaw.invention03 medical and health sciencesR5-9200302 clinical medicineLumbarRandomized controlled trialLaser therapylawPostural BalanceMedicineHumansLow back painBiology (General)General Pharmacology Toxicology and PharmaceuticsLead (electronics)Pain Measurementbusiness.industryPhysical therapy modalitiesGeneral NeuroscienceCell BiologyGeneral MedicineMiddle AgedLow back pain030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisAnesthesiaPostural balanceChronic DiseaseFemaleAnalysis of variancemedicine.symptombusinessResearch ArticleFollow-Up StudiesBrazilian Journal of Medical and Biological Research
researchProduct

Intracortical facilitation within the migraine motor cortex depends on the stimulation intensity. A paired-pulse TMS study

2018

Abstract Introduction Connectivity within the primary motor cortex can be measured using the paired-pulse transcranial magnetic stimulation (TMS) paradigm. This evaluates the effect of a first conditioning stimulus on the motor evoked potential (MEP) elicited by a second test stimulus when different interstimulus intervals are used. Aim of the present study was to provide, in patients suffering from migraine without aura (MwoA), additional information on intracortical facilitation (ICF), short intracortical inhibition (SICI), and long intracortical inhibition (LICI), using different intensities of the test stimulus (TS). Methods We enrolled 24 patients with episodic MwoA and 24 age- and sex…

0301 basic medicineAdultMaleMigraine without Auramedicine.medical_specialtyMotor cortex paired pulsemedicine.medical_treatmentRestlcsh:MedicineStimulationAudiologyStimulus (physiology)03 medical and health sciencesYoung Adult0302 clinical medicineHumansMedicineIctalEvoked potentialbusiness.industryElectromyographylcsh:RMotor CortexCortical excitabilityNeural InhibitionGeneral MedicineMiddle Agedmedicine.diseaseEvoked Potentials MotorTranscranial Magnetic StimulationTranscranial magnetic stimulation030104 developmental biologymedicine.anatomical_structureAnesthesiology and Pain MedicineMigraineFemaleNeurology (clinical)Primary motor cortexGlutamatebusiness030217 neurology & neurosurgeryResearch ArticleMotor cortexHuman
researchProduct

Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study.

2014

Background The purpose of this study was to evaluate the immunohistochemical expression of NF-κB and IL-6 in oral premalignant and malignant lesions and to investigate their possible correlation with the presence of subepithelial inflammation. Material and Methods Thirty two oral premalignant lesions, clinically compatible with leukoplakia or erythroplakia, were investigated. Microscopically, 11 of them showed hyperkeratosis and acanthosis (epithelial hyperplasia) and 21 showed dysplasia of varying degrees. Nine cases of OSCC and four control cases of normal oral mucosa were also included in the study. Immunohistochemical staining with NF-κB (p65) and IL-6 was performed. IL-6 and nuclear NF…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyHyperkeratosisOdontologíaAcanthosis03 medical and health sciences0302 clinical medicineMedicineHumansGeneral DentistryLeukoplakiaAgedMouth neoplasmAged 80 and overErythroplakiaOral Medicine and Pathologybusiness.industryInterleukin-6ResearchNF-kappa BMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludImmunohistochemistrystomatognathic diseases030104 developmental biologyOtorhinolaryngologyDysplasia030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASImmunohistochemistrySurgeryFemaleMouth NeoplasmsbusinessPrecancerous ConditionsImmunostainingLeukoplakiaMedicina oral, patologia oral y cirugia bucal
researchProduct

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey

2018

Abstract Background The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire‐sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE‐C1‐INH). Objective To report IOS data comparing demographic and icatibant treatment outcomes in patients with HAE‐C1‐INH from Germany to HAE‐C1‐INH patients from 11 other IOS countries. Methods A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE‐C1‐INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, …

0301 basic medicineAdultMalePediatricsmedicine.medical_specialtyTime FactorsC1 inhibitor deficiencyTime to treatmentDermatologyBradykininAutoimmune DiseasesTime-to-Treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanyBradykinin B2 Receptor AntagonistsmedicineHumansIn patientSymptom onsetRetrospective Studiesbusiness.industryAngioedemas HereditaryMiddle Agedmedicine.diseaseSymptom Flare UpHealth Surveys030104 developmental biologyInfectious Diseases030228 respiratory systemchemistryHereditary angioedemaObservational studyOriginal ArticleFemaleOutcome databusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Characterisation of a household norovirus outbreak occurred in Valencia (Spain)

2016

Background Human noroviruses (NoVs) are the main cause of non-bacterial gastroenteritis worldwide. Several studies have linked human susceptibility to NoVs with the expression of histo-blood group antigens (HBGAs). In January 2012, a NoV gastroenteritis outbreak affected a household in Valencia, Spain, and the personal susceptibility to NoV was investigated. Methods To reach this aim 8 members of the affected household were recruited for this study and their secretor status, ABO and Lewis antigens were determined. NoV-specific saliva IgA and serum IgG antibody titers were analyzed. Their capacity to block viral binding to saliva receptors was analyzed, using virus-like particles (VLPs) of t…

0301 basic medicineAdultMaleSalivaGenotypeIgGFUT2030106 microbiologyHisto-blood group antigensBiologymedicine.disease_causeDisease Outbreaks03 medical and health sciencesSecretorFecesfluids and secretionsstomatognathic systemABO blood group systemGenotypemedicineHumansChildSalivaCaliciviridae InfectionsBlood typeBinding assayFamily CharacteristicsNorovirusAntibody titerOutbreakVirus-like particlesMiddle AgedVirologyGastroenteritis030104 developmental biologyInfectious DiseasesSusceptibilitySpainImmunologybiology.proteinNorovirusFemaleAntibodyIgAResearch ArticleBMC Infectious Diseases
researchProduct

KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.

2017

Killer immunoglobulin-like receptors (KIRs) regulate the activation of Natural Killer cells through their interaction with human leukocyte antigens (HLA). KIR and HLA loci are highly polymorphic and certain HLA-KIR combinations have been found to protect against viral infections. In this study we analyzed whether the KIR/HLA repertoire may influence the course of hepatitis B virus (HBV) infection. Fifty-seven subjects with chronic hepatitis B (CHB), 44 subjects with resolved HBV infection, and 60 healthy uninfected controls (HC) were genotyped for KIR and their HLA ligands. The frequency of the HLA-A-Bw4 ligand group was higher in CHB (58%) than subjects with resolved infection (23%) (crude…

0301 basic medicineAdultMaleSettore MED/09 - Medicina InternaGenotypeSettore MED/17 - Malattie InfettiveKIR LigandHuman leukocyte antigenHLA-C AntigensBiologymedicine.disease_cause03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicVirologymedicineHumansGenetic Predisposition to DiseaseAlleleReceptorGeneAgedSettore MED/04 - Patologia GeneraleHepatitis B virusHepatologyHLA-A AntigensMiddle AgedVirologyHLA-AKIRs HLAA HBV030104 developmental biologyInfectious DiseasesTreatment OutcomeHLA-B AntigensReceptors KIR2DL3ImmunologyFemalePredictive variables030215 immunology
researchProduct

Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome.

2019

Abstract Background Patients with postthrombotic syndrome (PTS) treated with stents are at risk of stent thrombosis (ST). The incidence of ST in the presence and absence of anticoagulation therapy (AT) is unknown. Risk factors are not well understood. Patients and Methods From the prospective Swiss Venous Stent registry, we conducted a subgroup analysis of 136 consecutive patients with PTS. Incidence of ST was estimated from duplex ultrasound or venography, and reported for the time on and off AT. Baseline, procedural, and follow-up data were evaluated to identify factors associated with ST. Results Median follow-up was 20 (interquartile range [IQR] 9–40) months. AT was stopped in 43 (32%) …

0301 basic medicineAdultMalemedicine.medical_specialty2720 HematologyVenographySubgroup analysis610 Medicine & healthVena Cava Inferior030204 cardiovascular system & hematologyIliac VeinPostthrombotic Syndrome03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInterquartile rangeRisk FactorsmedicineAlloysHumansCumulative incidenceRegistries610 Medicine & healthStrokemedicine.diagnostic_testbusiness.industryIncidence (epidemiology)10031 Clinic for AngiologyIncidenceHazard ratioEndovascular ProceduresAnticoagulantsThrombosisHematologyPhlebographyFemoral VeinMiddle Agedmedicine.diseaseConfidence intervalSurgery030104 developmental biologyTreatment OutcomeFemaleStentsbusinessSwitzerlandFollow-Up StudiesThrombosis and haemostasis
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct